Maas Biolab enters Phase II for development of ALS drug
After successful completion of Phase I established initial Mitogard stability and drug safety for the new intrathecal route for cyclosporin, the amount of $894,000 for year two was
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
New investor Essex Woodlands Health Ventures led the round, with participation from existing investors Burrill & Company, HealthCare Ventures, Johnson & Johnson Development, Morgenthaler Ventures, Novartis BioVentures and
According to the company, HZT-501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, has demonstrated a statistically significant reduction in the incidence of non-steroidal anti-inflammatory drug